| 1. |
- Stacchiotti, S., et al.
(författare)
-
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
- 2021
-
Ingår i: ESMO Open. - : Elsevier BV. - 2059-7029. ; 6:3
-
Forskningsöversikt (refereegranskat)abstract
- Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. No active systemic agents are currently approved specifically for EHE, which is typically refractory to the antitumor drugs used in sarcomas. The degree of uncertainty in selecting the most appropriate therapy for EHE patients and the lack of guidelines on the clinical management of the disease make the adoption of new treatments inconsistent across the world, resulting in suboptimal outcomes for many EHE patients. To address the shortcoming, a global consensus meeting was organized in December 2020 under the umbrella of the European Society for Medical Oncology (ESMO) involving >80 experts from several disciplines from Europe, North America and Asia, together with a patient representative from the EHE Group, a global, disease-specific patient advocacy group, and Sarcoma Patient EuroNet (SPAEN). The meeting was aimed at defining, by consensus, evidence-based best practices for the optimal approach to primary and metastatic EHE. The consensus achieved during that meeting is the subject of the present publication.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Damasso, M., et al.
(författare)
-
Photometric follow-up of the 20 Myr old multi-planet host star V1298 Tau with CHEOPS and ground-based telescopes
- 2023
-
Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 680
-
Tidskriftsartikel (refereegranskat)abstract
- Context. The 20 Myr old star V1298 Tau hosts at least four planets. Since its discovery, this system has been a target of intensive photometric and spectroscopic monitoring. To date, the characterisation of its architecture and planets’ fundamental properties has been very challenging.Aims. The determination of the orbital ephemeris of the outermost planet V1298 Tau e remains an open question. Only two transits have been detected so far by Kepler/K2 and TESS, allowing for a grid of reference periods to be tested with new observations, without excluding the possibility of transit timing variations. Observing a third transit would allow for better constraints to be set on the orbital period and would also help in determining an accurate radius for V1298 Tau e because the previous transits showed different depths.Methods. We observed V1298 Tau with the CHaracterising ExOPlanet Satellite (CHEOPS) to search for a third transit of planet e within observing windows selected to test three of the shortest predicted orbital periods. We also collected ground-based observations to verify the result found with CHEOPS. We reanalysed Kepler/K2 and TESS light curves to test how the results derived from these data are affected by alternative photometric extraction and detrending methods.Results. We report the CHEOPS detection of a transit-like signal that could be attributed to V1298 Tau e. If so, that result would imply that the orbital period calculated from fitting a linear ephemeris to the three available transits is close to ~45 days. Results from the ground-based follow-up marginally support this possibility. We found that i) the transit observed by CHEOPS has a longer duration compared to that of the transits observed by Kepler/K2 and TESS; and ii) the transit observed by TESS is >30% deeper than that of Kepler/K2 and CHEOPS, and it is also deeper than the measurement previously reported in the literature, according to our reanalysis.Conclusions. If the new transit detected by CHEOPS is found to be due to V1298 Tau e, this would imply that the planet experiences TTVs of a few hours, as deduced from three transits, as well as orbital precession, which would explain the longer duration of the transit compared to the Kepler/K2 and TESS signals. Another and a priori less likely possibility is that the newly detected transit belongs to a fifth planet with a longer orbital period than that of V1298 Tau e. Planning further photometric follow-up to search for additional transits is indeed necessary to solve the conundrum, as well as to pin down the radius of V1298 Tau e.
|
|
| 8. |
|
|
| 9. |
- Sorbye, H, et al.
(författare)
-
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study
- 2013
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 24:1, s. 152-160
-
Tidskriftsartikel (refereegranskat)abstract
- As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67 < 55% was by receiver operating characteristic analysis the best cut-off value concerning correlation to the response rate. Patients with Ki-67 < 55% had a lower response rate (15% versus 42%, P < 0.001), but better survival than patients with Ki-67 >= 55% (14 versus10 months, P < 0.001). Platinum schedule did not affect the response rate or survival. The most important negative prognostic factors for survival were poor performance status (PS), primary colorectal tumors and elevated platelets or lactate dehydrogenase (LDH) levels. Advanced GI-NEC patients should be considered for chemotherapy treatment without delay.PS, colorectal primary and elevated platelets and LDH levels were prognostic factors for survival. Patients with Ki-67 < 55% were less responsive to platinum-based chemotherapy, but had a longer survival. Our data indicate that it may not be correct to consider all GI-NEC as one single disease entity.
|
|
| 10. |
|
|
